BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
BD (NYSE: BDX) reported positive nine-month results from the AGILITY trial for its Revello™ Vascular Covered Stent, showing high vessel patency and low reintervention rates in treating iliac artery disease. The study met its primary endpoint with a 2.8% failure rate, and patients showed improved mobility and symptoms. The trial is ongoing, with follow-up through 36 months. The device is CE marked but remains investigational in the U.S.
How this was made
The 30-second read
Why it matters
The trial’s early success supports BD’s claim of innovation in peripheral vascular care and may drive future sales once regulatory clearance is obtained.
Market read
Positive clinical data could lift BD’s stock and benefit the peripheral vascular device segment.
What to watch
Future data through 36 months could change the outlook; competition from other covered stent manufacturers remains strong.
Background
BD (Becton, Dickinson and Company) is a leading medical‑technology firm. The AGILITY trial evaluates its Revello Vascular Covered Stent for complex iliac artery disease.
Ticker impact
BD announced positive nine‑month AGILITY trial results for its Revello Vascular Covered Stent, showing 97.2% primary patency and low reintervention rates.
likely upward pressure as the market prices in the strong safety and efficacy outcomes.
First‑time disclosure of robust clinical results for a key device; no prior public data existed.
Market effects
May reinforce confidence in the broader peripheral vascular device market and could benefit peers with similar product pipelines.
U.S. and European investors likely to react; limited impact in Asia-Pacific.
Modest, confined to medical‑technology sector.
Counterpoint
If the device remains investigational in the U.S., revenue upside may be limited until FDA clearance.
Key entities
- personSean Lyden, M.D.
Global lead principal investigator for the AGILITY trial.
- productRevello Vascular Covered Stent
Nitinol self‑expanding stent with radial force tailored for iliac arteries.
